Inherited DNA changes linked to high blood pressure from bevacizumab in breast cancer
Studies inherited DNA from breast cancer patients who developed high blood pressure on bevacizumab.
Plain-language title generated from the registry record
Registry title: Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
Key facts
- Where
- Boston, United StatesSee the site
Where in United States
- Eastern Cooperative Oncology GroupBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Cancer Institute (NCI)
- Trial code
- NCT02610413
- Record updated
- 27 March 2026
- Original description
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with hypertension receiving bevacizumab for breast cancer. Studying samples of germline DNA in the laboratory from patients with hypertension receiving bevacizumab for breast cancer may help doctors learn about changes that occur in DNA and identify biomarkers related to hypertension.Read full original descriptionShow less
Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with hypertension receiving bevacizumab for breast cancer. Studying samples of germline DNA in the laboratory from patients with hypertension receiving bevacizumab for breast cancer may help doctors learn about changes that occur in DNA and identify biomarkers related to hypertension.
Inclusion: European American patients with deoxyribonucleic acid (DNA) available and designated case or control; Patients who developed grade 3-4 bevacizumab-induced hypertension during their treatment with bevacizumab; Patients who did not develop hypertension following a full course of treatment with bevacizumab.